ERBB2 and triple-negative breast carcinoma: Patients with CSF cytology confirmed LMD from HER2-positive or triple-negative breast cancer will undergo treatment with an intraventricular HER2/HER3 primed DCV with the primary objective of finding the maximum tolerated dose and secondary outcomes of OS and PFS.